IL1B and Guillain-Barre syndrome: Our previous study with earlier published data suggested that IVIgs used for the treatment of GBS suppress the levels of proinflammatory cytokines such as TNF-α and IL-1β during recovery, but remained relatively high in untreated patients [17, 75].